OncoMed raises $93 million in second round financing extension

Cancer stem-cell start up OncoMed has raised $93 million in a second round financing extension, bringing its total to around $154 million. The company, which has raised $204 million to date, plans to use the funds for its cancer stem-cell antibody programs, including its lead compound and a second antibody, through Phase 2 clinical trials.

London-based Nomura Phase4 Ventures Limited led the inside round extension, joined by previous investors US Venture Partners, Bay Partners, Morgenthaler Ventures, Latterell Venture Partners, The Vertical Group, Adams Street Partners, and DeNovo Ventures.

OncoMed also reports that it has established a strategic partnership with GlaxoSmithKline which the company claims could be worth as much as $1.4 billion.

To learn more about OncoMed:
- read this San Jose Business Journal story
- check out OncoMed's website

Suggested Articles

Presidential candidate Kamala Harris wants to get rid of the tax break drug companies get for DTC ads

Healthcare software company Phreesia closed its first day of trading as a public company Thursday about 40% above its set price.

Growing the biosimilar market could lead to significant healthcare cost savings, according to a new report.